SCHEMBL4899455

SCHEMBL4899455

CCOC(=O)n1cc(-c2ccc(C#N)cc2)n(Cc2ccc(C(F)(F)P(=O)(O)O)c(Br)c2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 12/20 0.40
PTPN2 P17706 7/20 0.40
PTPRC P08575 2/20 0.36
PTPN5 P54829 1/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
PGGT1B P53609 1/20 0.34
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4891972 0.87 PTPN1 (0.40) PTPN1PTPN2
SCHEMBL4893908 0.87 PTPN2 (0.39) PTPN1PTPN2PTPRCMAPTSMN1; SMN2
SCHEMBL4890705 0.82 PTPN1 (0.42) PTPN1PTPN2PTPRCPTPN5AR
SCHEMBL4899461 0.82 MAPT (0.36) MAPTTDP1LMNATSHRSMN1; SMN2
SCHEMBL4903207 0.79 NOTUM (0.37) MAPTSMN1; SMN2
SCHEMBL4899986 0.79 PTPN1 (0.34) PTPN1PTPN2
SCHEMBL4890738 0.78 PTPN1 (0.44) PTPN1PTPN2PTPRCPTPN5
SCHEMBL4901576 0.77 F2RL3 (0.43) PTPN1PTPN2PTPRCMAPTLMNA
SCHEMBL4890553 0.77 PTPN1 (0.40) PTPN1PTPN2PTPRCSMN1; SMN2
SCHEMBL5817911 0.77 PTPN1 (0.42) PTPN1PTPN2PTPRCMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS PTPN1 13/4885PTPN2 27/4885PTPRC 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.